Ministers are facing pressure to decide whether to exclude Chinese companies from operating in the UK’s genomics sector to safeguard health data from potential foreign exploitation. Concerns have been raised about the involvement of Chinese biotechnology firms, BGI Group and MGI Tech, in the genomics industry.
The UK is a leading figure in genomics research, which focuses on studying human genetic material for medical advancements. This field has the potential to revolutionize healthcare by offering personalized treatments to patients. However, there are fears surrounding the misuse of genomic data and how it could be exploited by foreign entities.
Chinese companies like BGI Group and MGI Tech have come under scrutiny due to worries about Beijing’s influence over new technologies. The ban on Huawei’s equipment from the UK’s 5G network in 2020 and security concerns related to TikTok’s parent company have further fueled apprehensions about Chinese involvement in sensitive sectors.
Shadow cabinet office minister John Glen has urged the government to consider excluding Chinese firms from the genomics sector, citing concerns that these companies may be used by Beijing to gather DNA data globally and dominate the industry supply chain. He highlighted how European countries and the US have implemented measures to mitigate the risks associated with Chinese influence in genomics.
In response to the pressure, Cabinet Office minister Abena Oppong-Asare stated that decisions to bar companies from operating in the UK would be made on a case-by-case basis after thorough investigations. She emphasized the importance of protecting patients’ data and engaging with data repositories to ensure up-to-date risk assessments are in place.
Both BGI Group and MGI Tech have denied any ties with the Chinese government, stressing that their research and services are conducted for civilian and scientific purposes. They have affirmed their commitment to data protection and compliance with relevant laws and regulations, including GDPR rules in Europe.
The debate over Chinese involvement in the UK’s genomics sector reflects broader concerns about safeguarding sensitive data and national security. As the government faces mounting pressure to address these issues, the decision to exclude foreign companies from critical industries like genomics will be carefully considered to protect the country’s interests and data privacy.
